Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-α-dependent pathway

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 6, 2014, Pages

  Yurdagul Jr, Arif ^a   Kleinedler, James J ^a   McInnis, Marshall C ^a   Khandelwal, Alok R ^a   Spence, Allyson L ^a   Orr, A Wayne ^a   Dugas, Tammy R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Endothelial; Estrogen receptor; Resveratrol; Sheer stress; Wound healing

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; RESVERATROL; SMALL INTERFERING RNA; CARDIOVASCULAR AGENT; ESTROGEN RECEPTOR; PACLITAXEL; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY INJURY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LAMINAR FLOW; LAMINAR SHEAR STRESS; LIPID DIET; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHEAR STRESS; VASCULAR SMOOTH MUSCLE; WOUND HEALING; ANIMAL; BLOOD FLOW; CAROTID ARTERY; CYTOLOGY; DRUG EFFECT; ENDOTHELIAL; INBRED MOUSE STRAIN; MECHANICAL STRESS; METABOLISM; PHYSIOLOGY; SHEAR STRENGTH; SHEER STRESS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ENDOTHELIAL; ESTROGEN RECEPTOR; RESVERATROL; SHEER STRESS; WOUND HEALING;

ANIMALS; CARDIOVASCULAR AGENTS; CAROTID ARTERIES; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE TYPE III; PACLITAXEL; REGIONAL BLOOD FLOW; SHEAR STRENGTH; SIGNAL TRANSDUCTION; STILBENES; STRESS, MECHANICAL; WOUND HEALING;

EID: 84900539922     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00892.2013     Document Type: Article

References (47)

1. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33: 387-398, 2002.
2. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV. Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol 272: H1996-H2003, 1997.
3. Bowers JL, Tylmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657-3667, 2000.
4. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 103: 423-428, 2001.
5. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 91: 327-387, 2011.
6. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 85: 9-23, 2005.
7. Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol 50: 83-93, 2007.
8. Filipe C, Lam Shang Leen L, Brouchet L, Billon A, Benouaich V, Fontaine V, Gourdy P, Lenfant F. Arnal JF, Gadeau AP, Laurell H. Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium. Am J Physiol Heart Circ Physiol 294: H2822-H2830, 2008.
9. Glantz SA. Primer of Applied Regression and Analysis of Variance. New York: McGraw-Hill, 1990.
10. Gotlieb AI, May LM, Subrahmanyan L, Kalnins VI. Distribution of microtubule organizing centers in migrating sheets of endothelial cells. J Cell Biol 91: 589-594, 1981.
11. Grandas OH, Mountain DH, Kirkpatrick SS, Cassada DC, Stevens SL, Freeman MB, Goldman MH. Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure. J Vasc Surg 49: 185-191, 2009.
12. Gu J, Wang CQ, Fan HH, Ding HY, Xie XL, Xu YM, Wang BY, Huang DJ. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J Cardiovasc Pharmacol 47: 711-721, 2006.
13. Hayashi S, Yamamoto A, You F, Yamashita K, Ikegame Y, Tawada M, Yoshimori T, Shimizu S, Nakashima S. The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol 175: 2226-2234, 2009.
14. Hsu PP, Li S, Li YS, Usami S, Ratcliffe A, Wang X, Chien S. Effects of flow patterns on endothelial cell migration into a zone of mechanical denudation. Biochem Biophys Res Commun 285: 751-759, 2001.
15. Hui DY. Intimal hyperplasia in murine models. Curr Drug Targets 9: 251-260, 2008.
16. In K, Park J, Park H. Resveratrol at high doses acts as an apoptotic inducer in endothelial cells. Cancer Res Treat 38: 6, 2006.
17. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996.
18. Khalil RA. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmaol 86: 1627-1642, 2013.
19. Khandelwal AR, Hebert VY, Dugas TR. Essential role of ER-α-dependent NO production in resveratrol-mediated inhibition of restenosis. Am J Physiol Heart Circ Physiol 299: H1451-H1458, 2010.
20. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 148: 969-976, 1996.
21. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 95: 1768-1772, 1997.
22. Lee B, Moon SK. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J Nutr 135: 2767-2773, 2005.
23. Li G, Chen YF, Greene GL, Oparil S, Thompson JA. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 100: 1639-1645, 1999.
24. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64: 1029-1036, 2003.
25. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 73: 792-796, 1993.
26. Ma Y, Qiao X, Falone AE, Reslan OM, Sheppard SJ, Khalil RA. Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat. Cell Physiol Biochem 26: 457-470, 2010.
27. Miller KM. A Drug-Eluting Stent Case Study: Taxus Express 2-from Development to Approval. New England Chapter Parenteral Drug Association Workshop (Online). http://www.pda.org/Chapters/North-Americacont/ New-England/Presentations/Development-and-Commercializationof-Combination-Products-A-Drug-Eluting-Stent-Case-Study-TAXUS-E. aspx [2004].
28. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91: 755-763, 1995.
29. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346: 1773-1780, 2002.
30. Nakamura Y, Suzuki T, Miki Y, Tazawa C, Senzaki K, Moriya T, Saito H, Ishibashi T, Takahashi S, Yamada S, Sasano H. Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol Cell Endocrinol 219: 17-26, 2004.
31. Yurdagul A Jr, Chen J, Funk SD, Albert P, Kevil CG, Orr AW. Altered nitric oxide production mediates matrix-specific PAK2 and NF-κB activation by flow. Mol Biol Cell 24: 398-408, 2013.
32. Pires NM, Jukema JW, Daemen MJ, Quax PH. Drug-eluting stents studies in mice: do we need atherosclerosis to study restenosis? Vascul Pharmacol 44: 257-264, 2006.
33. Rush JW, Quadrilatero J, Levy AS, Ford RJ. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med (Maywood) 232: 814-822, 2007.
34. Schwartz SM, Haudenschild CC, Eddy Endothelial regeneration EM. I. Quantitative analysis of initial stages of endothelial regeneration in rat aortic intima. Lab Invest 38: 568-580, 1978.
35. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43: 4, 1992.
36. Tan H, Jiang X, Yang F, Li Z, Liao D, Trial J, Magera MJ, Durante W, Yang X, Wang H. Hyperhomocysteinemia inhibits post-injury reendothelialization in mice. Cardiovasc Res 69: 253-262, 2006.
37. Trabattoni D, Bartorelli AL. Late occlusive in-stent restenosis of a bare-metal stent presenting with ST-elevation anterior MI: is restenosis better than a late stent thrombosis? Int J Cardiol 135: e65-e67, 2009.
38. Truelsen T, Gronbaek M, Schnohr P, Boysen G. Intake of beer, wine, and spirits and risk of stroke: the Copenhagen City heart study. Stroke 29: 2467-2472, 1998.
39. Ueda M, Graf R, MacWilliams HK, Schliwa M, Euteneuer U. Centrosome positioning and directionality of cell movements. Proc Natl Acad Sci USA 94: 9674-9678, 1997.
40. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, Dammacco F. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 11: 103-118, 2002.
41. Vorpahl M, Yazdani SK, Nakano M, Ladich E, Kolodgie FD, Finn AV, Virmani R. Pathobiology of stent thrombosis after drug-eluting stent implantation. Curr Pharm Des 16: 4064-4071, 2010.
42. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106: 1652-1658, 2002.
43. Wessely R, Blaich B, Belaiba RS, Merl S, Gorlach A, Kastrati A, Schömig A. Comparative characterization of cellular and molecular antirestenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost 97: 1003-1012, 2007.
44. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med 8: 3-17, 2001.
45. Wu Q, Chambliss K, Lee WR, Yuhanna IS, Mineo C, Shaul PW. Point mutations in the ERα Gαi binding domain segregate nonnuclear from nuclear receptor function. Mol Endocrinol 27: 2-11, 2013.
46. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 96: 5292-5297, 1999.
47. Zou J, Huang Y, Cao K, Yang G, Yin H, Len J, Hsieh TC, Wu JM. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci 68: 153-163, 2000.